2,520 Results Found

Background/Objectives: The clinical determinants and functional relevance of persistent lung ultrasound (LUS) abnormalities after COVID-19 pneumonia remain poorly characterized. We aimed to identify determinants of qualitative LUS abnormalities and g...

Introduction: The use of a lung ultrasound (LUS) score has been described in the early phases of neonatal respiratory distress syndrome; however, there is still no data regarding the application of the LUS score to neonates with a congenital diaphrag...

Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST₂) peptide agonist [¹⁷⁷Lu]Lu-DOTA-TATE is effective and well-established. Recent studies suggest improved therapeutic efficacy using the SST₂ peptide antag...

Recently, great interest has been gained regarding fibroblast activation protein (FAP) as an excellent target for theranostics. Several FAP inhibitor molecules such as [⁶⁸Ga]Ga-labelled FAPI-02, 04, 46, and DOTA.SA.FAPi have been introduced and are h...

Limited experiments have compared the treatment effects of repetitive cycles of radiolabelled somatostatin (SST) analogues. In vitro and in vivo experiments were conducted in an AR42J cancer cell model, comparing the antagonist [¹⁷⁷Lu]Lu-satoreotide...

Objective: To compare the effect of managing neonatal lung disease with lung ultrasound (LUS) or chest X-ray (CXR) monitoring on health outcomes and cost-effectiveness. Methods: The data obtained from the NICU of the Beijing Chaoyang District Materna...

Aqueous solutions of Lu³⁺- perchlorate, triflate and chloride were measured by Raman spectroscopy. A weak, isotropic mode at 396 cm⁻¹ (full width at half height (fwhh) at 50 cm⁻¹) was observed in perchlorate and triflate solutions. This m...

Background: Radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-617 represents an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). Its clinical positioning relative to standard therapies remains under discussion. Objective: To comp...

Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and out...

The fibroblast activation protein (FAP) is heavily expressed in fibroblasts associated with the tumor microenvironment, while the prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of malignant angiogenic processes. Previous...

Purpose: The aim of this paper was to investigate correlations between pre- therapeutic [⁶⁸Ga]Ga-DOTA-TOC uptake and absorbed dose to tumours from therapy with [¹⁷⁷Lu]Lu-DOTA-TATE. Methods: This retrospective study included 301 tumours from 54 GEP-NE...

In March 2022, [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto^TM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have pre...

Castration-resistant prostate cancer presents radiotherapeutic challenges, especially in optimizing the cytosolic internalization of therapeutic radiopharmaceuticals. This research aimed to design and evaluate in vitro, a new dimeric radiopharmaceuti...

[¹⁷⁷Lu]Lu-PSMA^I&T is widely used for the radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC). Since this kind of therapy has gained a large momentum in recent years, an upscaled production process yielding multiple pati...

Due to the nearly identical chemical properties of Lu and Yb, the production of no-carrier-added (NCA) ¹⁷⁷Lu faces significant challenges in their separation. Achieving efficient and streamlined separation of Lu and Yb is crucial for the production o...

Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [¹...

Since prostate cancer is the most commonly diagnosed malignancy in men, the theranostic approach has become very attractive since the discovery of urea-based PSMA inhibitors. Different molecules have been synthesized starting from the Glu-urea-Lys sc...

This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correc...

By reformulating the circuit system of Lü as a set of two second order differential equations, we investigate the nonlinear dynamics of Lü’s circuit system from the Jacobi stability point of view, using Kosambi–Cartan–Cher...

Background/Objectives: Accurate absorbed dose estimation is essential for optimising targeted radionuclide therapy (TRT) in metastatic castration-resistant prostate cancer, where kidney toxicity is dose-limiting. [¹⁷⁷Lu]Lu-rhPSMA-10.1 is a novel PSMA...

¹⁷⁷Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). ¹⁷⁷Lu-DOTATOC is a...

Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (...

This study aims to assess the change in uptake to reference organs, including the liver, parotid and salivary glands after radioligand therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA-617 in relation to pretreatment imaging metrics. Eighty-five patients with mCRPC...

[¹⁷⁷Lu]Lu-PSMA-617 improves outcomes in patients with PSMA-positive metastatic Androgen Pathway Modulation-Resistant prostate cancer (mAPMR) previously treated with androgen deprivation therapy, androgen receptor pathway inhibitors and taxane chemoth...

This work is dedicated to the preparation and characterization of the radio-, thermo-, and photoluminescent properties of Lu₂O₃:Eu and Lu₂O₃:Tb nanopowder (NPs) scintillators, prepared by means of hydrothermal processing, and their film analogues mad...

The conventional reaction yield evaluation for radioisotope production is not sufficient to set up the optimal conditions for producing radionuclide products of the desired radiochemical quality. Alternatively, the specific radioactivity (SA) assessm...

Aiming to expand the application of the SST₂R-antagonist LM4 (DPhe-c[DCys-4Pal-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH₂) beyond [⁶⁸Ga]Ga-DATA^5m-LM4 PET/CT (DATA^5m, (6-pentanoic acid)-6-(amino)methy-1,4-diazepinetriacetate), we now introduce AAZTA⁵-LM4 (AAZTA⁵...

Background/Objectives: Red bone marrow irradiation is a major concern for patients with advanced prostate cancer undergoing [¹⁷⁷Lu]Lu-PSMA therapy. However, low uptake in the red bone marrow and the presence of bone lesions complicate image-based red...

Background: We have performed a systematic review to evaluate the efficacy and safety of [¹⁷⁷Lu]Lu-DOTA-TATE, a radioligand therapy, in advanced somatostatin receptor-positive pheochromocytoma/paraganglioma (PPGL), thymic neuroendocrine tumor (NET),...

Among various activation functions, the Rectified Linear Unit (ReLU) has become the most widely adopted due to its computational simplicity and effectiveness in mitigating the vanishing-gradient problem. In this work, we investigate the advantages of...

Synthetic procedures to obtain size and shape-controlled microparticles hold great promise to achieve structural control on the microscale of macroscopic ceramic- or composite-materials. Lutetium oxide is a material relevant for scintillation due to...

Objectives: Eligibility for Lutetium-177 labeled prostate-specific membrane antigen ([¹⁷⁷Lu]Lu-PSMA) radioligand therapy depends on PSMA PET/CT interpretation and may vary across observers and centres. We aimed to identify imaging and clinical correl...

Xiud Yax Lus Qim or Yalu wang 亞魯王 (Ode to the King Yalu) is a type of oral performance inherited verbally and transmitted orally by dongb langf (donglang 東郎, chanters of Yalu wang) at funerals and festive occasions. As one of the most representative...

Radiolabeled Affibody-based targeting agent ¹⁷⁷Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding...

(1) Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) has shown remarkable results in patients with advanced prostate cancer. We aimed to evaluate the toxicity profile of the PSMA ligand [¹⁷⁷Lu]Lu-PSMA I&T....

The use of ²²⁵Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with ¹⁷⁷Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma...

Background: Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma (mCRPC). Concerns of potential nephrotoxicity are based on renal tubul...

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comp...

p53 is involved in DNA damage response and is an exciting target for radiosensitization in cancer. Targeted radionuclide therapy against somatostatin receptors with ¹⁷⁷Lu-DOTATATE is currently being explored as a treatment for neuroblastoma. The aim...

The LU factorization of very large sparse matrices requires a significant amount of computing resources, including memory and broadband communication. A hybrid MPI + OpenMP + CUDA algorithm named SuperLU3D can efficiently compute the LU factorization...

Baseline uptake on prostate-specific membrane antigen (PSMA)-targeted imaging is a prerequisite for radioligand therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA-617. This study aims to quantify lesion-based response to RLT in relation to pretreatment standard molec...

A new method of production of one of the most widely used isotopes in nuclear medicine, ¹⁷⁷Lu, with high chemical purity was developed; this method includes irradiation of the HfO₂ target with bremsstrahlung photons. The irradiated target was dissolv...

The peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTA-octreotate (LuTate) is recommended for different types of neuroendocrine tumors (NETs) which overexpress somatostatin receptors (SSTR). A combination with chemotherapy improves objectiv...

Background/Objectives: Radioligandtherapy (RLT) with [177Lu]Lu-PSMA has been newly introduced as a routine treatment for metastatic castration-resistant prostate cancer (mCRPC). However, not all patients can tolerate the entire therapeutic sequence,...

LuAG:Ce (Lu₃Al₅O₁₂:Ce) is one of the most important color converters in white lighting industry. Especially, LuAG:Ce film attracts more attention due to the outstanding advantages, such as the efficient heat dissipation, the saving of rare earth, and...

Introducing [¹⁷⁷Lu]Lu-PSMA-617 into metastatic hormone-sensitive prostate cancer (mHSPC) raises questions about patient selection and treatment sequencing. This non-systematic narrative review examines PSMAddition alongside evidence on alternative tr...

Although complex Lü systems have been considered in many studies, application of the self-time-delay synchronization (STDS) of complex Lü systems in secure speech communications does not appear to have been covered in much of the literature...

In vitro therapeutic efficacy studies are commonly conducted in cell monolayers. However, three-dimensional (3D) tumor spheroids are known to better represent in vivo tumors. This study used [¹⁷⁷Lu]Lu-PSMA-I&T, an already clinically applied radio...

Background/Objectives: Lutathera^® ([¹⁷⁷Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-end...

¹⁷⁷Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease t...